相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A review of estrogen receptor/androgen receptor genomics in male breast cancer
Tesa M. Severson et al.
ENDOCRINE-RELATED CANCER (2017)
MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death
Isabel Jaco et al.
MOLECULAR CELL (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Causes of urban-rural disparities in adjuvant chemotherapy (AC) for rectal cancer (RC).
Khodadad Rasool Javaheri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer
J. O'Shaughnessy et al.
ANNALS OF ONCOLOGY (2016)
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer
Cameron P. Capper et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer
Weimin Li et al.
CLINICAL CANCER RESEARCH (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
Charlotte Fribbens et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
Sean W Fanning et al.
eLife (2016)
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
M. Dowsett et al.
LANCET (2015)
Endocrine resistance in breast cancer - An overview and update
Robert Clarke et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Zhenfei Li et al.
NATURE (2015)
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Lucy R. Yates et al.
NATURE MEDICINE (2015)
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
Gaia Schiavon et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Targeting the Androgen Receptor in Breast Cancer
KeeMing Chia et al.
CURRENT ONCOLOGY REPORTS (2015)
Mechanisms of aromatase inhibitor resistance
Cynthia X. Ma et al.
NATURE REVIEWS CANCER (2015)
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer
Yassine Rechoum et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers
Ricardo Ribas et al.
BREAST CANCER RESEARCH (2014)
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Dawn R. Cochrane et al.
BREAST CANCER RESEARCH (2014)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
Juliet Richards et al.
CANCER RESEARCH (2012)
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
Marion T. Weigel et al.
BREAST CANCER RESEARCH (2012)
Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
Rong Hu et al.
CLINICAL CANCER RESEARCH (2011)
Expression of androgen receptors in primary breast cancer
S. Park et al.
ANNALS OF ONCOLOGY (2010)
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells
Francesca De Amicis et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials
Christos J. Markopoulos
CANCER AND METASTASIS REVIEWS (2010)
Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities
Roland Hjerpe et al.
EMBO REPORTS (2009)
ChIP-seq: Using high-throughput sequencing to discover protein-DNA interactions
Dominic Schmidt et al.
METHODS (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Norman Williams
LANCET ONCOLOGY (2008)
Cancer as an evolutionary and ecological process
Lauren M. F. Merlo et al.
NATURE REVIEWS CANCER (2006)
Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation
JS Lewis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling
LA Martin et al.
ENDOCRINE-RELATED CANCER (2005)
Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal
JS Lewis et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter
R Métivier et al.
CELL (2003)
Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation
LA Martin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling
G Reid et al.
MOLECULAR CELL (2003)
Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation
CMW Chan et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2002)
Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol
RXD Song et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy
PE Lonning et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent
DL Stenoien et al.
NATURE CELL BIOLOGY (2001)
分享论文
